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Leishmaniasis is an infectious disease that affects both animals and humans, 
caused by flagellated parasites belonging to the genus Leishmania. The disease 
is estimated to reach about 700,000 to 1 million people, causing the deaths of 
20 to 30,000 individuals annually. Thus, the present study aims to perform mo-
lecular docking tests and evaluation of antileishmania activity in vitro of a ru-
thenium complex with epiisopiloturine and nitric oxide. AutoDockTools-1.5.6 
software was used to perform molecular docking tests. Molecular targets were 
considered rigid, and Epiruno2 considered flexible. The genetic algorithm La-
marckian (AGL) with global search and pseudo-Solis and Wets with local 
search were the methods adopted in the docking. The most promising results 
of molecular interaction were achieved in the targets Pteridine reductase and 
UDP-glucose Pyrophosphorylase with rates of −10.68 Kcal∙mol−1 and −10.51 
Kcal∙mol−1, respectively. This demonstrates that Epiruno2 has molecular affinity 
with the targets of L. major. In vitro assays prove the antileishmania activity of 
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Leishmaniasis is a disease that affects more than 98 countries worldwide, with 
about 700,000 to 1 million new cases reported annually, and an annual rate of 20 
to 30,000 deaths [1]. There are several ways for the disease to manifest clinically, 
and may present as cutaneous, mucocutaneous and visceral. Infection with Leish-
mania major (L. major) species has a chronic evolution that affects the structures 
of the nasopharyngeal epidermis and cartilage, either localized or diffuse [2]. The 
parasitic cycle results from the abundance of carbohydrates on the surface of 
Leishmania, which includes lipophosphoglycans, glycosylphosphatidylinositol 
lipid-anchored proteins and proteophosphoglycans [3]. These glycoproteins are 
part of the promastigote infectious glycocalyx, which is the most important 
process in host infectivity [4] and phlebotomine interaction [5]. 
After diagnosis, the patient undergoes treatment that depending on the in-
fecting strain will be treated with some of the drugs available on the pharma-
ceutical market, they are: pentavalent antimonial; AmBisomew; liposomal; am-
photericin B; miltefosine and diamidines, among others. All of these drugs are 
potentially toxic and have reduced efficacy in addition to adverse side effects. 
That in many cases, the patient chooses not to undergo treatment so that he does 
not suffer from side effects caused by drugs [6] [7]. 
Besides this problem, the pharmaceutical industries neglect investments in the 
search for new pharmacological agents that present high inhibition rates with 
new mechanisms of action and low toxicity. This lack of interest is related to mar-
ket demand, as it is a neglected disease, that is, it affects only underdeveloped 
and developing countries, the sector has high risks of not making profits on their 
investments, because the population would not be able to afford it. With the 
costs of treatment, even the state would not be able to finance the services of-
fered by the industries [8]. 
Thus, there is a clear need to search for new compounds with pharmacological 
potential and low toxicity by alternative methods that bring reliability in their 
results, speed and cost benefit. Thus, computational quantum chemistry presents 
itself as a promising alternative, using several computational tools that predict 
molecular properties related to a pharmacological potential. Using the laws of 
quantum chemistry and various programming techniques that are capable of 
predicting energy state, molecular structures, vibrational frequencies of atomic 
and molecular systems and molecular interaction between two molecules de-
vel-oping virtual models saving time and materials that would be wasted on ex-
periments in the field laboratory [9] [10]. 
the complex in the face of promastigote forms with inhibition of growth, con-
cluding through this study that the Epiruno2 complex has antileishmania activity. 
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In this sense, ruthenium (Ru) complexes have become attractive in pharma-
cological studies because they have low toxicity and are an excellent conductor 
of energy when dealing with a transition metal, where it plays an important role 
in the bioactive process of a compound in reaction with a target disease, having 
little energy loss in its path [11] [12]. The Ru complex with epiisopiloturin and 
nitric oxide (Epiruno2) was synthesized by Rocha (2018) in anti-schistosoma 
mansoni studies, where the Epiruno2 complex showed schistosomicidal activity 
in sílico and ex vivo studies. There was a 10-fold increase in the biological activ-
ity of Epiisopiloturin (EPI) when coupled with the Ru complex against Schisto-
soma parasites, eliminating 60% of male worms at a concentration of 50 µM 
within 72 hours, showing antiparasitic activity [13]. 
Associated with the antiparasitic schistosomicidal effect presented by the Epi-
runo2 complex in studies by Rocha (2018), we assume that the complex has anti-
leishmania activity. Thus, the present study aims to perform molecular docking 
tests and evaluation of antileishmania activity in vitro of a ruthenium complex 
with epiisopiloturine and nitric oxide. 
2. Materials and Methods 
2.1. Molecular Docking 
The 3D molecules of L. major targets were extracted from the PDB (Protein data 
Bank) database with codes 5g20 (Glycyl Peptide N-tetradecanoyltransferase); 5nzg 
(UDP-glucose Pyrophosphorylase); 5c7p (Nucleoside diphosphate kinase); 1e7w 
(Pteridine reductase); and 1ezr (Nucleoside hydrolase) [14] prepared for dock-
ing by removing mutant chains and all water molecules, ions and other groups 
using Chimera v.13.1 software [15] [16]. 
The three-dimensional molecular structure of the Epiruno2 complex was de-
signed using GaussView 5.0 software [17] and optimized by DFT (Density Func-
tional Theory) calculation using the B3lyp functional and the 6-311++G (d, p) 
available in Gaussian 09W software [18] [19]. 
The molecular docking process followed the protocol developed by Rocha and 
collaborators, with some modifications [20]. All molecular docking procedures 
were performed by AutoDockTools-1.5.6 software [21]. L. major targets and the 
Epiruno2 complex were prepared for docking simulations, where targets were 
considered rigid and Epiruno2 was considered flexible. Partial charges were cal-
culated after the addition of all hydrogens. The nonpolar hydrogen atoms of the 
protein and binder were subsequently fused. A 60 × 60 × 60 point cubic box with 
a spacing of 0.375 Å between grid points was generated for the simulations. The 
molecular affinity grid centers were defined from the coordi-nates of the atoms 
of their respective active sites Asn376, Lys380, Gly91, Asn109 and Asp15, re-
spectively. 
The Lamarckian global search (LGA) genetic algorithm [22] and the pseu-
do-Solis and Wets [23] local search (LS) methods were applied in the search for 
molecular docking. The Epiruno2 complex was subjected to 100 independent 
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runs of molecular coupling simulations [24]. The remaining parameters were set 
to default values. 
Molecular docking analysis focused on the results that presented lower fitting 
conformation with lower abindG  energy, in addition to the interactions by hy-
drogen bridge and inhibition constant presented by the Epiruno2 complex in the 
of the molecular targets of L. major. 
2.2. In Vitro Trials on Promastigote forms MHOM/IL/80/Friedlin  
of L. major 
For in vitro assays, the method adopted by Carneiro and collaborators was used, 
with some modifications [25]. The MHOM/IL/80/Friedlin promastigotes of L. 
major were donated by the Laboratory of Antileishmania Activity, located at the 
Research Core in Medicinal Plants of the Federal University of Piauí—UFPI and 
cultivated in Schneider media (Sigma, USA), supplemented with 10% bovine fetal 
serum (BFS) (Sigma, USA) and penicillin-streptomycin 10,000 IU/10mg (Sigma, 
USA) at 26˚C in a greenhouse of biological oxygen demand (BOD). 
L. major promastigote forms MHOM/IL/80/Friedlin in log phase were seeded 
1 × 106 parasites per well in a 96-well cell culture microplate containing supple-
mented Schneider medium and Epiruno2 at serial concentrations of 800 to 6.25 
µg/mL, respectively. Then the plates were incubated in a BOD greenhouse at 
26˚C. After 48 h resazurine (1 mM) was added and the plate was re-infiltrated in 
the BOD incubator for another 6 h. Then the spectrophotometer reading was 
performed to obtain the optical density at 550 nm. Negative control was per-
formed with Schneider medium at 0.2% DMSO and considered as 100% viability 
of the parasites. The amphotericin B (Amp-B) at a concentration of 2 µg/mL was 
used as a positive control to validate the experiment. 
3. Results and Discussion 
3.1. Molecular Docking 
The evaluation criteria were defined by the results that showed lower cluster 
conformation with lower abindG  energy, besides the hydrogen bridge interac-
tions and inhibition constant presented by the Epiruno2 complex against the L. 
major molecular targets. 
The molecular docking between the Epiruno2 complex and the 1e7w protein 
obtained the lowest abindG  energy among all molecular couplings performed in 
this study, obtaining an energy of −10.68 Kcal∙mol−1 and an inhibition constant 
of 14.8 nM (Table 1). This low abindG  energy indicates high molecular affinity of 
the complex with the target protein [26]. Thus, inhibiting its action would be to 
interrupt the disease development process, since the 1e7w enzyme has a function 
of reducing conjugated and unconjugated pterins, one example is biopterin and 
dihydrobiopterin (DHB), followed by 5, 6, 7, 8-tetrahydrobiopterin (THB) or 
DHF folate. It is the only protein known to reduce biopterin in Leishmania, 
proving to be essential for in vivo growth through genetic knockout studies [27]. 
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bindG∆   
(kcal∙mol−1) 
Kib (µM) 
Number of independent 
docking runs 
Number of conformations 
in the first ranked cluster 
Amino acids that interact through 
hydrogen bondsc 
Epiruno2/1e7w −10.68 14.8 nM 100 7 Asp232, Lys198, Ser111, Ser227 
Epiruno2/5nzg −10.51 19.74 nM 100 6 Asp221, Gly220, Lys95 
Epiruno2/5g20 −9.65 83.81 nM 100 81 - 
Epiruno2/5c7p −8.22 935.7 nM 100 43 Arg104, Asn114, Ser98 
Epiruno2/1ezr −8.19 996.06 nM 100 4 Pro11, gln40 
Note: Epiruno2—ruthenium complex with epiisopiloturine and nitric oxide; 1e7w—Pteridine reductase; 5nzg—UDP-glucose Pyrophosphorylase; 
5g20—Glycyl Peptide N-tetradecanoyltransferase; 5c7p—Nucleoside diphosphate kinase; and 1ezr—Nucleoside hydrolase. (Araújo et al., 2020). 
 
The most intense interactions between the target protein and the Epiruno2 
complex occur between the residues Asp232, Lys198, Ser111 and Ser227, places 
where the highest intermolecular forces act (Figure 1). 
The Epiruno2 complex also showed excellent molecular affinity results with 
the target protein 5nzg of L. major, obtaining a abindG  energy of −10.51 Kcal∙mol−1 
(Table 1) and formation of three hydrogen bridges located on amino acids Asp211, 
Gly220 and Lys95, where the most intense interactions between the complex and 
the target protein occur (Figure 1). This may be related to UGP (UDP—glucose 
pyrophosphorylase) catalyzing the synthesis of activated form glucose, UDP-Glc, 
uridine triphosphate (UTP) and glu-cose-1-phosphate (Glc-1p). Because the 
UDP-Glc reaction is critical in the production of carbohydrates such as cell surface 
glycans and other pathogen processes becoming an attractive target in interac-
tion and molecular inhibition studies [28] [29] [30]. The resulting inhibition 
constant was 19.74 nM, presenting antileishmania inhibitory activity of the Epi-
runo2 complex against target protein 5nzg (Table 1). 
This result indicates that the Epiruno2 complex has antileishmania inhibitory 
activity, since docking studies analyze the inhibitory action of coupled compounds 
at the active site of the target protein [26] even if there is a difference between in 
sílico and in vitro experiments, the results tend to differ, where in sílico studies 
by molecular docking pre-dict quickly and reliably if a compound has biological 
activity and experimental labora-tory studies validate their analyzes, complement-
ing each other, providing technical via-bility in the results presented [31] [32]. 
The 5g20 protein also showed molecular affinity with the Epiruno2 complex 
obtaining attractive abindG  energy in docking molecular affinity studies with −9.65 
Kcal∙mol−1 and an inhibition constant of 83.81 nM [26] (Table 1). This molecu-
lar interaction did not result in hydrogen bridges, unlike previous interactions 
between the Epiruno2 complex with the 1e7w and 5nzg proteins that had 4 and 3 
hydrogen bridges, respectively, however, the interactions in the Val374, Leu227 
and His219 residues make intense interactions in the active site borders of the 
protein, in particular the interactions Val374 with O1 and Leu227 with O2 and  
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Figure 1. Molecular docking between Epiruno2 complex and 1e7w and 5nzg target proteins. (a) Docking 
at target protein active site 1e7w; (b) molecular interaction between Epiruno2 and target protein 
1e7w; (c) Docking at 5nzg target protein active site; (d) molecular interaction between Epiruno2 and 
5nzg target protein. 
 
both residues with C8 (Figure 2). These interactions at the edges of the active site 
make the Epiruno2 complex have a very promising high inhibitory action, and the 
tertiary structure is part of recognition elements that facilitate the molecular in-
teractions between protein and ligand, in this case the Epiruno2 complex [33] [34]. 
Molecular docking between the 5c7p protein and the Epiruno2 complex 
formed three hydrogen bridges at amino acids Arg104, Asn114 and Ser98 
(Figure 2) and showed abindG  energy of −8.22 Kcal∙mol
−1 and an inhibition con-
stant of 935.7 nM (Table 1). These results are promising against this indispensa-
ble protein for the maintenance of intracellular nucleoside triphosphate (NTP) 
levels [35]. They carry the γ-phosphoryl group from an NTP to a nucleoside di-
phosphate (NDP) through a functional scheme called ping-pong involving the 
covalent intermediate phosphohistidine. Eukaryotic NDKs are composed of 15 
to 18 KDA subunits with similarities in their general structures and a conserved 
active site [36] [37]. 
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Figure 2. Molecular docking between the Epiruno2 complex and the 5g20, 5c7p and 1ezr proteins. (a) Docking at active site of protein 
5g20; (b) molecular interaction between 5g20 protein and Epiruno2 complex; (c) molecular interaction between 5c7p protein and 
Epiruno2 complex; (d) Docking at active site of protein 1ezr; (e) molecular interaction between 1ezr protein and Epiruno2 complex. 
 
The 1ezr protein can be identified in free extracts of Leishmania cells, is also 
present in several parasitic protozoa. It is a protein useful in parasitic infections, 
acting as a catalyst for the hydrolysis of both purine and pyrimidine nucleosides 
[38] [39], where its inhibition is fundamental for the treatment of L. major. In 
this sense, the Epiruno2 complex presented interesting interaction and molecular 
affinity results, obtaining a abindG  energy of −8.19 Kcal.mol
−1 and an inhibition 
constant of 996.06 nM [26] (Table 1). The most intense interactions between the 
complex and the protein occur at residues Pro11 and Gln40, the two hydrogen 
bonds formed (Figure 2). 
3.2. In Vitro Trials on Promastigote Forms MHOM/IL/80/Friedlin  
of L. major 
In these trials we evaluated the leishmanicidal effects of the Epiruno2 complex 
against L. major promastigote MHOM/IL/80/Friedlin parasites. The Epiruno2 
complex showed 50.53% inhibition of promastigote growth at a concentration of 
800 µg/mL (Figure 3), a significant reduction by analyzing the half maximal in-
hibitory concentration (CI-50) (Table 2) showing antileishmania activity, con-
firming the results presented in sílico tests by molecular docking. However, these 
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values are not considered clinically relevant, according to Santos et al. [40], 
which defines in their studies that only IC-50 lower than 500 µg/mL can be con-
sidered therapeutically relevant. 
It is observed that the results presented in molecular docking analyzes were 
more promising than the results presented in vitro assays. This may be related to 
the topological polar surface area (TPSA), which uses functional groups obtained 
from a structural database, avoiding calculations of the ligand’s three-dimensional 
(3D) structures, in this case the Epiruno2 complex or the confirmation of which 
conformation. Since this biological method is relevant, this method is used in 2D 
structures for 14 sets of diverse pharmacological activity data. This methodology 
is promising for classic 2D descriptors such as calculated LogP (ClogP) and cal-
culated molar refractivity (CMR) in the 2D-QSAR literature [41]. 
The discovery of new antileishmania chemical compounds has long been rea-
lized from the isolation of plant extracts. There are already several extracts and 
compounds that have proven antileishmania activity on promastigote and amas-
tigote forms of through in vitro assays [42] [43] [44]. Despite several microbio-
logical studies, several analyzes of new compounds extracted from natural and 
synthetic resources are still needed, as the search for new pharmacological po-
tential leishmanicide has been important, since the drugs in the pharmacological 
market have high toxicity and reduced efficacy [6] [45]. 
 
 
Figure 3. IC-50 of the Epiruno2 complex against L. major promastigotes. 
 
Table 2. IC-50 values of L. major promastigotes in the presence of the Epiruno2 complex. 
 Epiruno2 complex  
L. major  MHOM/IL/80/Friedlin 
IC-50  800 µg/mL 
Note: IC-50 – half maximal inhibitory concentration (Araújo et al., 2020). 
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4. Conclusions 
The Epiruno2 complex presented antileishamania activity both in sílico studies 
by molecular docking and in vitro study. Its best molecular affinity parameter 
presented in docking studies was for target proteins 1e7w and 5nzg with abindG  
energies −10.68 Kcal∙mol−1 and −10.51 Kcal∙mol−1, respectively. In addition to 
these two targets, it was found that the complex has molecular affinity for the 
other molecular targets of L. major analyzed in this study. 
In vitro assays proved the antileishmania activity of the complex against L. 
major promastigotes MHOM/IL/80/Friedlin with significant growth inhibitions. 
However, the values are not considered clinically relevant, concluding from in 
sílico and in vitro studies that the Epiruno2 complex has antiparasitic activity 
that can be tested on other Leishmania targets such as L. amazonensis and L. 
Chagasi and also in other pathogens. 
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